---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001690"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:50:38.434365+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics Q4 revenue up 145% to $20.4M; FY2025 guidance $80-85M

## Summary
- Q4 net sales $20.4M (+145% YoY); FY2024 net sales $65.1M (+443% YoY). Installed base 15,298 users (+564%).
- Operating loss Q4 $13.0M (neg 64% of sales); net loss $18.1M. Full year operating loss $45.3M.
- Cash $103.6M at Dec 31, 2024; raised ~$206M net from IPO/private placement in Jan 2025.
- FY2025 guidance: revenue $80-85M, >20% new patient starts from PBP channel, gross margin ≥50%.
- Prime Therapeutics added iLet to national commercial formulary; first-to-market integration with Abbott FreeStyle Libre 3 Plus.

## SEC filing metadata
- accession: 0001171843-25-001690
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184325001690/0001171843-25-001690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184325001690/f8k_032525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001690
- JSON: https://secwatch.observer/filing/0001171843-25-001690.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.